Af­ter sweep of deals in 2023, Gilead to fo­cus on 'late re­search, ear­ly de­vel­op­men­t' pipeline

Gilead is still hunt­ing for deals, par­tic­u­lar­ly in vi­rol­o­gy, on­col­o­gy and in­flam­ma­tion.

Dur­ing Tues­day’s fourth-quar­ter earn­ings call, CEO Daniel O’Day said M&A de­ci­sions will be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER